Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 15;11(1):2101769. doi: 10.1080/2162402X.2022.2101769

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Targeting SCD1 combined with RT triggers immunogenic ferroptosis. Suppressing ferroptosis attenuates the uptake of cancer cells by DCs. (a) Extracellular ATP release in KYSE70 cells following different concentrations of MF-438. (b) RT combined with MF-438 resulted in enhanced extracellular ATP release in KYSE70 cells. (c) Extracellular ATP release in KYSE410 cells following different concentrations of MF-438. (d) RT combined with MF-438 resulted in enhanced extracellular ATP release in KYSE410 cells. (e) Calreticulin cell surface exposure in KYSE70 cells following different concentrations of MF-438. (f) Calreticulin cell surface exposure in KYSE70 cells following different doses of RT combined with MF-438. (g) Calreticulin cell surface exposure in KYSE410 cells following different concentrations of MF-438. (h) Calreticulin cell surface exposure in KYSE410 cells following different doses of RT combined with MF-438. (i) Extracellular HMGB1 release in KYSE70 cells following different concentrations of MF-438. (j) RT combined with MF-438 resulted in enhanced extracellular HMGB1 release in KYSE70 cells. (k) Extracellular HMGB1 release in KYSE410 cells following different concentrations of MF-438. (l) RT combined with MF-438 resulted in enhanced extracellular HMGB1 release in KYSE410 cells. (m-n) The uptake of ferroptotic cells by DCs after treated with MF-438, RT, or the combined regimen. (o-p) The uptake of ferroptotic cells by DCs after treated with Fer-1, RT, or the combined regimen. Data are expressed as means ± SD (n = 3), n.s., non-significant, p > .05; *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.001; ****p ˂ 0.0001.

Abbreviations: ATP: adenosine triphosphate; DCs: dendritic cells; HMGB1: High mobility group box protein 1; RT: radiation therapy; SCD1: stearoyl-coa desaturase.